Skip to main content
TipRanks
Go Ultimate75% OFF

Genscript Biotech (GNNSF) Q2 2026 Earnings Report

23 Followers

GNNSF Q2 2026 EPS Results

Actual EPS
-$0.06
Consensus EPS
$0.00
Beat/Miss
Missed by -$0.06
One Year Ago EPS
-$0.02

GNNSF Q2 2026 Revenue Results

Actual Revenue
$403.17M
Expected Revenue
$383.94M
Beat/Miss
Beat by +$19.23M
YoY Revenue Growth
-21.77%

Earnings Announcement Details

Quarter
Q2 2026
Date
08/17/2026
Time
Before Open
Conference Call
Monday, August 17, 2026
GNNSF Upcoming Earnings

Genscript Biotech's next earnings date is estimated for March 24, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

GNNSF Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 17, 2026|% Change Since:20.72%|
Earnings Call Sentiment|Positive

Overall the call was strongly positive: the company reported robust top-line growth (USD 404.2M, +27.3%), record adjusted net profit (+203.3% to USD 62.5M), significant margin expansion and raised guidance, while highlighting clear strategic advantages in AI-enabled validation and a strong balance sheet. The main negatives are a still-unprofitable ProBio (though materially improved), Bestzyme's modest growth and widened operating loss, and execution/demand risks tied to the pace of AIDD adoption and scaling protein-side automation. On balance, highlights substantially outweigh lowlights.

Company Guidance

Management raised full‑year guidance: Life Science Services revenue growth 25–30% with adjusted gross margin >55% and adjusted operating margin >25%; ProBio revenue growth 25–30% with positive EBITDA expected in 2027; and Bestzyme revenue growth 8–10% with adjusted gross margin >43%. This follows a strong H1 baseline (group revenue US$404.2M, +27.3% YoY; adjusted net profit US$62.5M, +203.3%; group gross profit US$206.7M, +48%); LSG delivered US$319M revenue (+28.8%), adjusted gross profit US$185M (+46.1%) and adjusted operating profit US$94M (+102.8%) with adjusted gross margin 57.8% (55.4% ex U.S. tariff refunds) and operating margin 29.5% (27.1% same basis); ProBio H1 revenue US$61.1M (+34.2%), adjusted gross profit US$8.3M and adjusted EBITDA loss narrowed to US$6.5M (vs. -US$16.8M); Bestzyme H1 revenue US$30.4M (+7.4%) and adjusted gross profit US$13M (+14%). Management also disclosed H1 CapEx US$48.4M and full‑year CapEx ~US$130M, cash ≈US$830M, a 1.5x YoY surge in gene‑to‑protein ROI, and expects AIDD orders to double in H2 as a driver of continued upside.

  • Strong Group Revenue GrowthTotal revenue reached USD 404.2 million, up 27.3% year-over-year, driven by broad-based demand across segments.
  • Record Adjusted Net Profit and Gross Profit ExpansionAdjusted net profit reached USD 62.5 million, up 203.3% year-over-year (record for any half); group gross profit was USD 206.7 million, up 48.0% year-over-year, significantly outpacing revenue growth.
  • Life Science Group (LSG) Growth and Margin ImprovementLSG revenue was USD 319.0 million, up 28.8% YoY; adjusted gross profit USD 185.0 million, up 46.1% YoY; adjusted operating profit USD 94.0 million, up 102.8% YoY. Adjusted gross margin reached 57.8% (55.4% excl. U.S. tariff refunds) and adjusted operating margin reached 29.5% (27.1% on same basis).
  • AI-Driven Validation Platform and Operational AdvantagesGenScript highlighted a 4-day 'AI-to-biology' validation engine, ~60% of labs equipped with AI-driven automated workstations, processing >4,000 designs/day and sequence-to-data turnaround as fast as 4 days—positioned to capture high-frequency AIDD demand and command premium pricing.
  • ProBio Revenue and Orders MomentumProBio revenue reached USD 61.1 million, up 34.2% YoY; new orders grew 54% YoY (biologics orders +62.1%, advanced therapy orders +34.9%), backlog building and international/China orders showing strong expansion.
  • ProBio Profitability TrajectoryProBio adjusted gross profit improved to USD 8.3 million (from ~USD 2.7 million prior year) and adjusted EBITDA loss narrowed to USD 6.5 million from USD 16.8 million (improvement of over USD 10 million), signaling operating leverage and progress toward profitability.
  • Bestzyme R&D and AI IntegrationBestzyme revenue USD 30.4 million, up 7.4% YoY; adjusted gross profit USD 13.0 million, up 14% YoY. AI-enabled protein design doubled positive hit rates, shortened R&D cycles, and improved product-level gross margins (examples: +7% and +6% for specific products).
  • Raised Full-Year GuidanceLSG guidance raised to 25–30% revenue growth with adjusted gross margin >55% and adjusted operating margin >25%; ProBio revenue guidance raised to 25–30% with expectation of positive EBITDA in 2027; Bestzyme revenue guidance 8–10% with gross margin >43%.
  • Strong Financial Position and Capital PlanH1 CapEx was USD 48.4 million with full-year CapEx guidance ~USD 130 million; cash and cash equivalents approximately USD 830 million and management indicated no need for equity financing to support expansion.
  • Platform ROI and ScalabilityInvestment payback and capacity utilisation improving: gene-to-protein platform ROI surged 1.5x YoY in H1, with management targeting rapid capacity scaling (doubling throughput periodically) to capture AIDD demand.

GNNSF Earnings History

GNNSF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 24, 20272026 (Q4)0.01--0.23――
Aug 17, 20262026 (Q2)0.00-0.06-0.02-168.18% (-0.04)
Mar 15, 20262025 (Q4)-0.03-0.231.48-115.54% (-1.71)
Aug 17, 20252025 (Q2)0.08-0.02-0.0873.49% (+0.06)
Mar 12, 20252024 (Q4)―1.48-0.062449.21% (+1.54)
Aug 09, 20242024 (Q2)-0.01-0.08-0.04-88.64% (-0.04)
Mar 10, 20242023 (Q4)-0.05-0.06-0.04-40.00% (-0.02)
Aug 20, 20232023 (Q2)―-0.04-0.0630.16% (+0.02)
May 08, 20232023 (Q1)―--0.12―
Mar 30, 20232022 (Q4)-0.06-0.04-0.9695.31% (+0.91)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed